Fri Sep 20 12:38:59 UTC 2024: ## Edgestream Partners Invests in Hologic, Other Institutional Investors Active in Q4

**[City, State] – September 20, 2024** – Edgestream Partners L.P. has acquired a new stake in Hologic, Inc. (NASDAQ:HOLX), a leading provider of women’s health diagnostics and medical imaging systems, during the second quarter, according to the company’s recent 13F filing with the Securities and Exchange Commission (SEC). The investment firm purchased 22,841 shares of HOLX stock, valued at approximately $1,696,000.

Edgestream’s investment follows a wave of activity by other institutional investors in the fourth quarter. Notably, Norges Bank bought a new position in Hologic worth approximately $217,529,000. Jump Financial LLC and Coldstream Capital Management Inc. also acquired new stakes in the company, valued at $419,000 and $305,000 respectively. PNC Financial Services Group Inc. increased its holdings in Hologic by 0.9%, owning 31,933 shares worth $2,282,000 after purchasing an additional 288 shares. D.A. Davidson & CO. also acquired a new position in Hologic, valued at $204,000. Institutional investors now hold 94.73% of the company’s stock.

Hologic stock opened at $82.40 on Friday, with a 50-day simple moving average of $80.63 and a 200-day simple moving average of $77.01. The company boasts a market capitalization of $19.23 billion, a PE ratio of 42.04, a PEG ratio of 2.53, and a beta of 0.98. Hologic has a twelve-month low of $64.02 and a twelve-month high of $84.67.

Several research analysts have weighed in on Hologic recently. Evercore ISI lifted their price target on HOLX from $76.00 to $78.00 and gave the company an “in-line” rating. Royal Bank of Canada reaffirmed a “sector perform” rating with a $82.00 price target, while Stephens restated an “overweight” rating with a $92.00 price objective. Needham & Company LLC reaffirmed a “buy” rating with a $90.00 target price. Finally, StockNews.com downgraded Hologic from “strong-buy” to “buy.”

Overall, four equities research analysts have rated the stock with a hold rating, while eight have issued a buy rating. According to MarketBeat.com, Hologic currently has an average rating of “Moderate Buy” and a consensus target price of $87.60.

In recent insider transactions, Brandon Schnittker sold 476 shares of Hologic stock on August 6th at an average price of $83.11, for a total value of $39,560.36. Stephen P. Macmillan, CEO of Hologic, sold 3,672 shares on July 17th at an average price of $80.13, for a total transaction of $294,237.36. Over the last 90 days, insiders have sold 18,280 shares of company stock worth $1,469,973. Insiders currently own 1.75% of the stock.

Hologic, Inc. develops, manufactures, and supplies diagnostic products, medical imaging systems, and surgical products for women’s health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. They provide a range of products including molecular diagnostic assays, cytology systems, and fetal fibronectin tests, among others.

For more information and to receive daily news and ratings for Hologic, visit MarketBeat.com.

Read More